Bill
Bill > H1137
MA H1137
MA H1137Relative to cancer patient access to biomarker testing to provide appropriate therapy
summary
Introduced
03/29/2021
03/29/2021
In Committee
03/30/2022
03/30/2022
Crossed Over
Passed
Dead
12/31/2022
12/31/2022
Introduced Session
192nd General Court
Bill Summary
Relative to insurance coverage for biomarker testing for certain cancer patients. Financial Services.
AI Summary
This bill aims to provide cancer patients with advanced or metastatic stage 3 or 4 cancer access to biomarker testing without the need for prior authorization. Biomarker testing is a diagnostic procedure that analyzes a patient's biospecimen, such as tissue, blood, or other bodily fluids, to identify DNA and/or RNA alterations that can help guide their treatment. The bill amends various chapters of the Massachusetts General Laws to prohibit insurance providers from requiring prior authorization for this type of testing for eligible cancer patients.
Committee Categories
Business and Industry, Health and Social Services
Sponsors (8)
Meghan Kilcoyne (D)*,
Pat Duffy (D),
Carmine Gentile (D),
Jessica Giannino (D),
Jim Hawkins (D),
Chris Hendricks (D),
Natalie Higgins (D),
Dave Robertson (D),
Last Action
Accompanied a study order, see H5222 (on 09/15/2022)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://malegislature.gov/Bills/192/H1137 |
| Bill | https://malegislature.gov/Bills/192/H1137.pdf |
Loading...